Point-of-Care Diagnostic Patent Landscape 2026
Point-of-Care Diagnostic Patent Landscape in 2026
The point-of-care diagnostic patent space is heavily concentrated, with Becton Dickinson & Co commanding a commanding lead and the top five filers collectively accounting for the majority of activity among the hundred largest filers. Annual volume peaked in 2022 and has since eased, though publication lag means the most recent periods remain under-counted.
Becton Dickinson leads a concentrated field with a steep tier gap
Becton Dickinson & Co sits atop the
The top five filers collectively hold 51% of the combined total among the hundred largest filers, a degree of concentration typical of a field where a single incumbent has built deep portfolio barriers. University Health Network ranks second with 98 patent records, followed by Hemex Health Inc (38), Colgate Palmolive Co (30), and Zeteo Tech Inc (29), forming a thin second tier far below the leader.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | BECTON DICKINSON & CO | 231 | |
| 2 | University Health Network | 98 | |
| 3 | Hemex Health Inc | 38 | |
| 4 | Colgate Palmolive Co | 30 | |
| 5 | Zeteo Tech Inc | 29 | |
| 6 | University of Tasmania | 28 | |
| 7 | Siemens Healthcare Diagnostics Inc | 18 | |
| 8 | Vectracor Inc | 16 | |
| 9 | Ischemia Technologies Inc | 15 | |
| 10 | Talis Biomedical Corp | 12 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Micromass UK Ltd | 12 | |
| 12 | HydraDx | 11 | |
| 13 | Sentilus Holdco LLC | 10 | |
| 14 | Ortho Clinical Diagnostics Inc | 10 | |
| 15 | Radboud University Medical Center | 10 | |
| 16 | Regents of the University of California | 9 | |
| 17 | Case Western Reserve University | 8 | |
| 18 | Gate Scientific Inc | 8 | |
| 19 | Fio Corp | 8 | |
| 20 | DMI Biosciences Inc | 8 |
Becton Dickinson’s lead implies that challengers seeking to compete on portfolio breadth face a significant accumulation deficit; differentiation through focused technology niches or adjacent branches is a more realistic near-term path for most entrants.
Figures covering the most recent 18–24 months are subject to publication lag and should be treated as floors rather than final counts. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2022; diagnostics and material analysis dominate the technology mix
The annual filing trend reveals a field that expanded through 2022 before easing, while the technology composition chart shows A61B (Diagnosis & Surgery) as the overwhelmingly dominant branch, with G01N (Material Analysis & Testing) and B01L (Lab Apparatus) as secondary clusters.
Annual filing trend
Filings rose from 77 records in 2017 to a peak of 112 in 2022, then eased to 35 in 2023. Values for 2024–2026 remain under-counted due to publication lag and should not be read as a structural decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & Surgery) accounts for the largest share of classified records, reflecting the clinical-device orientation of the corpus. G01N (Material Analysis & Testing) and B01L (Lab Apparatus) are meaningful secondary branches, while C12Q (Enzymes/DNA), G16H (Healthcare Informatics), and G06T (Image Processing) represent smaller but structurally distinct clusters.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
A point-of-care diagnostic system for diagnosis an…
The present invention relates to a portable point-of-care diagnostic system (1) which can determine the amount of phenylalanine in the blood by performing rapid blood analysis for early diagnosis and follow-up of phenylketonuria disease. (excerpt from the patent abstract)
Open this patent in Eureka →| # | Patent | Citations |
|---|---|---|
| 1 | Point of care diagnostic systems | 380 |
| 2 | Point of care diagnostic systems | 368 |
| 3 | Device and method for fluorescence-based imaging a… | 367 |
| 4 | Method and apparatus for a point of care device | 282 |
| 5 | Method and apparatus for a point of care device | 279 |
| 6 | Method and apparatus for a point of care device | 247 |
| 7 | Portable medical diagnostic systems and methods us… | 237 |
| 8 | Fully automated vascular imaging and access system | 218 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
Four structural observations — maturity, concentration, collaboration, and geography — collectively shape where new entrants and challengers should direct resources.
Post-peak field with easing annual volume
The lifecycle evidence places the field in a decline stage, with annual filings easing back from the 2022 peak. On a multi-year basis the corpus remains substantial at 684 patent families, but the directional signal suggests foundational device-platform IP is maturing. New entrants should prioritize adjacent or emerging branches rather than replicating established claim territory in core diagnostic instrumentation.
Post-peak · 2022 highSingle dominant incumbent, thin challenger tier
With 51% of activity among the top 100 filers concentrated in five applicants — and Becton Dickinson alone holding more records than the next four combined — the field resembles an oligopoly with one clear platform leader. Challengers such as University Health Network (98 records, +17% recent trend) and Zeteo Tech Inc (29 records) have established footholds but face a structural gap in portfolio depth. Competing head-to-head on breadth is inadvisable for most new entrants.
High concentration · top-5 = 51%Minimal co-filing activity detected
The collaboration evidence shows only a single co-filing relationship in the dataset: Rigas Anastasia co-filing with HydraDx. This near-absence of formal co-applicant activity suggests the field operates largely through internal R&D programs rather than consortium or university-industry partnerships — an unusual characteristic that may reflect the proprietary nature of device-level IP in regulated diagnostic markets. Ecosystem collaboration partnerships remain an under-exploited structural lever.
Low collaboration densityUS-centric with EPO and PCT coverage; India emerging
The United States leads as the primary filing jurisdiction, followed by Europe (EPO) and WIPO (PCT) for international protection. India’s position as the fourth-ranked jurisdiction — ahead of Australia and Canada — signals growing commercial or manufacturing interest in that market. China and Japan each show minimal filing activity relative to their diagnostic market sizes, which may indicate either deliberate geographic focus by incumbents or an under-covered opportunity for regionally oriented entrants.
US-led · India risingGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| RIGAS ANASTASIA | HydraDx | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Becton Dickinson dominates; University Health Network grows steadily in diagnostics and optical analysis
Two applicants stand meaningfully above the rest: Becton Dickinson & Co as the clear platform incumbent, and University Health Network as the most credible institutional challenger. Both concentrate heavily in A61B (Diagnosis & Surgery), but diverge in secondary emphasis.
Becton Dickinson & Co
Becton Dickinson & Co holds 231 patent records, anchored in A61B 5 (Diagnosis & Surgery, 227 records), with secondary positions in B01L 3 (Lab Apparatus) and G01N 33 (Material Analysis). Recent filing momentum is strongly positive at +118% versus the prior period, indicating the company is actively reinforcing its lead rather than managing a static legacy portfolio.
patent records: 231University Health Network
University Health Network ranks second with 98 patent records and shows a +17% recent trend — steady institutional growth rather than a surge. Its technology emphasis spans A61B 5 (Diagnosis & Surgery, 96 records) and G01N 21 (optical/spectroscopic material analysis, 86 records), giving it a distinctive optical-diagnostics profile that partially differentiates it from Becton Dickinson’s broader device platform.
patent records: 98| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Becton Dickinson & Co | 83 | ▲ +118% |
| University Health Network | 14 | ▲ +17% |
| Hemex Health Inc | 8 | ▼ -43% |
| Zeteo Tech Inc | 13 | ▼ -13% |
| University of Tasmania | 2 | ▲ new entrant |
| Siemens Healthcare Diagnostics Inc | 3 | ▲ new entrant |
Under-served branches in informatics, enzyme-based assays, and image processing
Relative to the dominant A61B cluster, several IPC branches show lower filing density yet are technically adjacent to point-of-care applications — making them worth monitoring for entrants seeking less contested territory.
G16H · Healthcare Informatics
With 65 classified records, G16H represents a sparse presence relative to the core diagnostic device branches. Point-of-care systems increasingly require connectivity, data aggregation, and clinical decision-support layers — areas where informatics IP could be foundational. The realistic entry path is through software-defined diagnostics platforms that pair with existing hardware, a route that avoids direct competition with Becton Dickinson’s device-level portfolio.
Search this in Eureka →C12Q · Measuring & Testing Involving Enzymes or DNA
C12Q accounts for 68 classified records — low relative to the A61B and G01N anchors — despite molecular and enzymatic assays being a core growth vector in decentralized diagnostics. The sparsity may reflect that molecular POC IP is filed under clinical-device codes rather than chemistry codes, or that this sub-domain remains genuinely under-patented at the point-of-care layer. Entrants with nucleic-acid amplification or enzymatic biosensor expertise have a plausible path into this branch with limited incumbent overlap.
Search this in Eureka →How leading applicants differ across technology routes
Strength of each leader across the main technology routes.
| Player | A61B 5 · Diagnosis & surgery | G01N 33 · Material analysis & testing | G01N 21 · Material analysis & testing | B01L 3 · Lab apparatus | A61B 10 · Diagnosis & surgery |
|---|---|---|---|---|---|
| Becton Dickinson & Co | Strong · 227 | Moderate · 48 | Absent | Moderate · 50 | Absent |
| University Health Network | Strong · 96 | Emerging · 11 | Strong · 86 | Absent | Moderate · 38 |
| Hemex Health Inc | Strong · 38 | Strong · 25 | Emerging · 7 | Strong · 22 | Absent |
| Zeteo Tech Inc | Strong · 29 | Strong · 23 | Absent | Absent | Strong · 19 |
| Colgate Palmolive Co | Strong · 30 | Absent | Moderate · 14 | Absent | Absent |
| University of Tasmania | Strong · 28 | Absent | Absent | Absent | Moderate · 12 |
| Micromass UK Ltd | Strong · 12 | Strong · 12 | Absent | Absent | Strong · 12 |
Frequently asked questions
Becton Dickinson & Co leads with 231 patent records, more than double the second-ranked filer, University Health Network (98 patent records). Their portfolio is concentrated in A61B 5 (Diagnosis & Surgery) with secondary positions in lab apparatus and material analysis.
Annual filing volume peaked in 2022 at 112 records and has eased since. The lifecycle evidence characterizes the field as post-peak. Recent-year figures (2024–2026) remain under-counted due to publication lag and should be treated as minimum floors.
The United States leads as the primary filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). India ranks fourth — ahead of Australia and Canada — signaling meaningful commercial interest in that market. China and Japan show comparatively low filing activity.
A61B (Diagnosis & Surgery) is the dominant branch by a wide margin. G01N (Material Analysis & Testing) and B01L (Lab Apparatus) are the primary secondary clusters. C12Q (Enzymes/DNA), G16H (Healthcare Informatics), and G06T (Image Processing) are smaller but structurally distinct areas.
G16H (Healthcare Informatics) and C12Q (Measuring & Testing Involving Enzymes or DNA) show relatively sparse filing density compared to the dominant clinical-device branches. Both are technically adjacent to point-of-care applications and may represent lower-competition entry paths for specialized filers.
Collaboration is minimal: the evidence shows only a single co-filing relationship — between Rigas Anastasia and HydraDx. Most activity appears to stem from internal corporate or institutional R&D programs, with co-applicant partnerships representing an under-utilized structural approach in this field.
Map your own position in the point-of-care diagnostic landscape
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.